Endo
Malvern, US · Founded 2023 · Delaware corporation · 1 known investors
Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.
Founders & leadership
SH
Scott HirschDirector
PE
Paul EfronDirector
PH
Paul HerendeenDirector
MY
Marc YoskowitzDirector
PB
Patrick BarryExecutive Officer
BC
Blaise ColemanPresident; Chief Executive Officer
MM
Matthew MalettaExecutive Vice President; Chief Legal Officer; Secretary
SL
Sophia LangloisDirector
FR
Frank RacitiVice President; Controller; Chief Accounting Officer
MB
Mark BradleyExecutive Vice President; Chief Financial Officer
AP
Andy PasternakDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$170.6MraisedMay 2024 · 404 investors · PharmaceuticalsRule 506(b)
▶$170.6MraisedMay 2024 · 404 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott HirschDirector
- Paul EfronDirector
- Paul HerendeenDirector
- Marc YoskowitzDirector
- Patrick BarryExecutive Officer
- Blaise ColemanExecutive Officer, Director
- Matthew MalettaExecutive Officer
- Sophia LangloisDirector
- Frank RacitiExecutive Officer
- Mark BradleyExecutive Officer, Director
- Andy PasternakDirector
- Offering amount
- $170.6M
- Amount sold
- $170.6M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.